Have any questions? 706-721-6582 or cts@augusta.edu
- D18-11141: Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Clinical Trial
D18-11141: Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
This study will investigate whether a new experimental treatment, DFP 10917, will be an effective and safe treatment option for patients with relapsed/refractory acute myelogenous leukemia (AML). The purpose of this study is to compare the safety and effectiveness of DFP-10917 versus available treatments that are considered Standard of Care (SOC) for patients who have not responded to previous chemotherapy treatments (refractory AML) or have relapsed following remission with prior treatment (relapsed AML). If it is determined during screening that you are eligible for the study, you will be randomized by a computer to receive either DFP-10917 (the experimental group) or standard treatment (control group) by chance. Neither you nor your study doctor can choose the group you will be in.
Eligibility Criteria
- Male or female, aged 18 years or older Subjects with confirmed Acute Myelogenous Leukemia (AML) Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures